Abstract
Background: Few studies have directly compared virus-specific antibodies and their neutralizing capacity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild type (WT) and circulating variants of concern despite the reported high efficacy of messenger RNA (mRNA)- and vector-based vaccines.
Objective: We assessed SARS-CoV-2 spike protein region 1 (S1)-specific antibodies of BNT162b2, mRNA-1273, and ChAdOx1 vaccinated as well as convalescent coronavirus disease 2019 (COVID-19) patients. We also determined the neutralization ability against SARS-CoV-2 WT and B.1.1.7 (Alpha), B1.1.7 E484K (Alpha-E484K), B.1.351 (Beta), and B.1.617.2 (Delta) variants.
Methods: Serum samples of 107 fully vaccinated or convalescent individuals were analyzed for anti-SARS-CoV-2-S1 IgG and IgA as well as for total anti-SARS-CoV-2 receptor binding domain Ig. Furthermore, neutralization capacity as 50% and 90% neutralization titer values against SARS-CoV-2 WT virus and circulating variants were determined.
Results: We observed a robust IgG response in all participants; however, the highest titers were detected in mRNA-based vaccine recipients. In case of serum IgA responses, the difference between mRNA- and vector-based vaccines or convalescent patients was even more pronounced. Interestingly, all 3 vaccines could neutralize all tested variants of concern in addition to WT virus, but in some individuals, only low or no neutralization, especially against Alpha-E484K and the Delta variant, was detected.
Conclusion: Our study of the efficacy of various COVID-19 vaccines found that mRNA-1273 had the highest neutralization abilities compared to BNT162b2 and ChAdOx1. COVID-19 convalescent patients demonstrated the most heterogeneous range of antibody titers and neutralization abilities, making it hard to assess protection. Furthermore, a significant positive relation between antibodies and the 50% neutralization titer values for immunized and convalescent individuals was determined.
Keywords: IgG and IgA antibodies; SARS-CoV-2; vaccines; variants of concern; virus neutralization.
【저자키워드】 SARS-CoV-2, Vaccines, variants of concern, Virus neutralization, IgG and IgA antibodies, 【초록키워드】 COVID-19, coronavirus disease, IgG, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, COVID-19 vaccine, antibody, B.1.351, mRNA-1273, neutralization, variant, Delta, B.1.617.2, severe acute respiratory syndrome Coronavirus, delta variant, virus, anti-SARS-CoV-2, variants, Spike protein, Receptor binding domain, BNT162b2, serum, Convalescent patients, B.1.1.7, IgA, mRNA, SARS-CoV-2 spike protein, Antibody titer, Virus neutralization, Alpha, E484K, Beta, neutralizing capacity, respiratory, convalescent, wild type, ChAdOx1, patients, Antibody titers, convalescent patient, specific antibodies, neutralization capacity, in some, IgG response, (Beta), (Alpha), Messenger RNA, acute respiratory syndrome, acute respiratory syndrome coronavirus, serum samples, acute respiratory syndrome coronavirus 2, recipients, All participants, IgA antibodies, heterogeneous, positive, convalescent individuals, neutralization titer, IgA responses, virus-specific antibodies, serum sample, mRNA-based vaccine, neutralization ability, circulating variants, S1 IgG, WT virus, SARS-CoV-2 WT, neutralize, COVID-19 convalescent patients, immunized, robust, convalescent individual, highest, tested, analyzed, reported, addition, was determined, demonstrated, individuals, circulating variant, COVID-19 convalescent patient, of BNT162b2, 【제목키워드】 COVID-19 vaccine, Analysis, Comparative, neutralizing effect,